Semax vs Selank: Two Heptapeptides Compared

Semax and Selank are often shelved together, described together, and confused with each other — two seven-amino-acid peptides, both developed in Russia, both studied in the context of brain and stress biology, and both ending in the same three residues. Semax was built from a fragment of adrenocorticotropic hormone, a pituitary stress hormone. Selank was built from tuftsin, a fragment of an immunoglobulin involved in immune signaling. Two different parent molecules and two different research lineages converge on a shared stabilizing tail — Pro-Gly-Pro — that both peptides carry. This comparison reviews their structures, origins, proposed mechanisms, and evidence.

The central point is structural kinship amid different origins. A shared tail does not make the two peptides interchangeable, and findings reported for one do not transfer to the other. Each peptide has to be judged by its own experiments.

Semax at a Glance

• Identity: synthetic heptapeptide, the ACTH(4-7) fragment extended at its C-terminus with Pro-Gly-Pro
• Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
• Molecular weight: approximately 813.9 Da
• Parent molecule: adrenocorticotropic hormone (ACTH), residues 4 to 7
• Origin: developed at the Institute of Molecular Genetics, Russian Academy of Sciences
• Research contexts in the literature: rodent models of stress, ischemia and cholinergic function, and gene-expression studies

Semax begins with ACTH(4-7), the Met-Glu-His-Phe segment near the N-terminus of ACTH. In animal work, fragments in this region showed central activity separate from the full hormone's corticosteroid-releasing role. The design kept that four-residue core and added Pro-Gly-Pro, a motif from the glyproline family studied for resistance to rapid enzymatic breakdown. The result is a compact, fully synthetic heptapeptide with no exact natural counterpart.

Selank at a Glance

• Identity: synthetic heptapeptide, a tuftsin analogue extended at its C-terminus with Pro-Gly-Pro
• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
• Molecular weight: approximately 751.9 Da
• Parent molecule: tuftsin, the Thr-Lys-Pro-Arg fragment of the Fc region of immunoglobulin G
• Origin: developed in the same Russian peptide-research tradition, as a stabilized tuftsin analogue
• Research contexts in the literature: rodent studies of anxiety-related behavior, enkephalin metabolism, memory models and BDNF regulation

Selank begins at a different place. Tuftsin is a tetrapeptide released from immunoglobulin G and studied originally for its effects on phagocytic cells of the immune system. Its sequence, Thr-Lys-Pro-Arg, forms Selank's first four residues, and Pro-Gly-Pro was appended to extend its persistence, as with Semax. The finished molecule is an immune-derived fragment wearing the same stabilizing tail as an ACTH-derived fragment — a resemblance of engineering, not of ancestry.

Two Origins, Two Russian Research Lineages

Both peptides emerged from a Soviet and Russian peptide-science tradition that treated short regulatory peptides as a distinct class — small fragments of larger proteins, carrying signaling information, that could be redesigned for stability. Within that tradition, Semax and Selank belonged to different programs. Semax came from work on melanocortin fragments at the Institute of Molecular Genetics of the Russian Academy of Sciences, where ACTH fragments were explored for central effects independent of hormonal activity.

Selank came from the tuftsin line of work, where the starting observation was an immunomodulatory fragment and the interest broadened toward central effects reported in animal studies, including behavior in stress and anxiety-related models. Vyunova and colleagues, reviewing the molecular aspects of Selank's biological activity in Protein and Peptide Letters in 2018, described it explicitly as a tuftsin analogue combining the parent tetrapeptide with the glyproline tail. Same country, same design trick, different scientific conversations.

Mechanisms Compared

Neither peptide has a single, settled mechanism in the way a well-characterized receptor drug does. What the literature offers is proposed mechanisms tied to particular experiments, and the two sets differ.

Selank: enkephalin protection and neurotrophin regulation

The most specific mechanistic proposal for Selank concerns enkephalins, endogenous opioid peptides rapidly broken down by dedicated enzymes. Zozulya and colleagues reported in the Bulletin of Experimental Biology and Medicine in 2001 that Selank inhibited enkephalin-degrading enzymes, and proposed this inhibition as a possible mechanism for the anxiolytic-like activity observed in their animal work. On this account, Selank does not substitute for an enkephalin; it slows the removal of enkephalins already present, changing the duration of an existing signal.

A second Selank thread is brain-derived neurotrophic factor, or BDNF. Kolik and colleagues reported in the Bulletin of Experimental Biology and Medicine in 2019 that, in rats exposed to ethanol in a memory-impairment model, Selank was associated with regulation of BDNF content in the hippocampus and prefrontal cortex alongside the behavioral measures in that model. That is a region-specific finding in one rodent paradigm, not a general claim about memory.

Semax: cholinergic neurons, stress responses and gene expression

Semax research has followed other systems. Grivennikov and colleagues, reporting in Restorative Neurology and Neuroscience in 2008, studied the effects of Semax on rat basal forebrain cholinergic neurons — the cell population that supplies much of the cortex and hippocampus with acetylcholine and that features prominently in attention and memory research.

Stress biology is a second Semax thread. Yatsenko and colleagues reported in Doklady Biological Sciences in 2013 that the heptapeptide attenuated the effects of chronic unpredictable stress in rats, using the behavioral and physiological readouts of that paradigm. Gene-expression studies form a third thread: Russian groups have used Semax in rodent ischemia and related models to track changes in expression of genes involved in vascular, immune and neurotrophic pathways. Those datasets show a broad transcriptional footprint in rodents — a reason for caution, since such changes do not identify a single mechanism or predict an outcome outside the model.

What the Research Literature Actually Studied

The work is predominantly preclinical: rodent models, tissue studies and molecular assays, published over roughly three decades. For Selank, the recurring designs are anxiety-related behavioral models in rodents, biochemical work on enkephalin-degrading enzymes, and studies such as the Kolik group's 2019 ethanol and memory model with BDNF readouts. For Semax, the recurring designs are rodent stress paradigms such as the chronic unpredictable stress work of Yatsenko and colleagues in 2013, ischemia-related models with gene-expression endpoints, and cellular work such as the basal forebrain cholinergic neuron study of Grivennikov and colleagues in 2008.

One study is especially useful because it examined both peptides in the same framework. Panikratova and colleagues, reporting in Doklady Biological Sciences in 2020, used a functional connectomic approach to study Selank and Semax effects, examining how each peptide was associated with patterns of functional connectivity in the brain in their experimental setting. Head-to-head work of this kind is rare. It treats the two peptides as distinct inputs to a network rather than assuming the shared tail makes them equivalent — a connectomic analysis in a specific setting, not a clinical comparison.

None of these results — a rodent behavioral readout, a change in hippocampal BDNF in rats, a gene-expression shift, or a connectivity pattern — amounts, singly or together, to a demonstration of an effect in humans.

Stability and Structure: The Shared Glyproline Tail

The one true structural link is the ending both sequences share: Pro-Gly-Pro. Proline-rich endings belong to the glyproline family, studied extensively as stabilizing elements. A C-terminal proline arrangement is harder for many common peptidases to process than an exposed, flexible tail, so appending Pro-Gly-Pro was a rational way to give a short, otherwise fragile fragment a longer working life in biological media.

Beyond the tail, the molecules diverge in ways that matter analytically and biologically. Semax contains methionine, with the oxidation sensitivity that sulfur-containing residue brings during synthesis, handling and storage. Selank contains two basic residues, lysine and arginine, giving it a different charge profile and different chromatographic behavior. Their masses differ by roughly 62 Da, and their parent biology points to different proposed targets. The shared tail explains why they are compared; everything else explains why the comparison cannot end there.

Reading these two literatures well requires keeping the model and the readout attached to every claim. A stress paradigm in rats answers a question about that paradigm; a gene-expression panel answers a question about transcription in the tissue sampled, at the time sampled; a connectomic analysis answers a question about correlated activity in a defined network. Each design is informative on its own terms, and each becomes misleading when its readout is detached from its setting and repeated as a property of the peptide itself. That habit of careful reading — model, tissue, readout, and only then interpretation — is the most useful skill this comparison can offer a researcher approaching either compound for the first time.

Analytical Verification

Because Semax and Selank are close in size and share a tail, analytical verification has to be sequence-specific rather than generic. Three standard checks apply. Identity by mass spectrometry should confirm the intact molecular mass for the named peptide — approximately 813.9 Da for Semax and approximately 751.9 Da for Selank — a difference mass spectrometry can distinguish unambiguously if the full spectrum is examined. For Semax, the spectrum and chromatogram also deserve a look for the oxidized methionine species, which adds about 16 Da and signals degradation.

Purity by HPLC quantifies the intact peptide against related impurities, including truncated sequences missing part of the shared tail — impurities that a mass check on the main peak alone would not quantify. Net peptide content completes the specification, because a lyophilized heptapeptide powder includes counter-ions and water, and a purity percentage does not state how much of the weighed material is peptide at all. Together — correct mass, chromatographic purity, and stated net content — these checks make the label claim for Semax 10MG or Selank 10MG testable.

Limits and Open Questions

The limits of this field are clear. First, the literature for both peptides is concentrated in Russian-language journals and Russian research groups, with much of the work in venues such as Doklady Biological Sciences and the Bulletin of Experimental Biology and Medicine; independent replication by unrelated laboratories in other countries is limited. Second, the evidence is predominantly preclinical — rodent models, cell and tissue work, gene-expression and connectomic analyses — and preclinical findings do not establish effects in humans. Third, mechanism remains plural and unsettled for both molecules: enkephalin-enzyme inhibition and BDNF regulation for Selank, cholinergic and transcriptional effects for Semax, are proposed mechanisms supported by particular experiments, not a complete account of either peptide.

Neither Semax nor Selank is approved by the U.S. Food and Drug Administration, and neither has the large, controlled human trial record that approval would require. Open questions remain: whether the rodent findings replicate independently, whether the proposed mechanisms hold up, and whether the 2020 connectomic results can be reproduced. They are well-defined synthetic heptapeptides with a shared stabilizing design, distinct parent molecules, and an interesting, largely preclinical research record. NUPEPS PEPTIDES supplies Semax and Selank strictly as laboratory research materials, for laboratory research use only.